Orgenesis (STU:45O0) Cyclically Adjusted PB Ratio: (As of Sep. 06, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:45O0 Orgenesis Inc STU:45O0
12 GF Score
Price €3.40
View Full Analysis

What is Orgenesis Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Orgenesis  (STU:45O0) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Orgenesis Cyclically Adjusted PB Ratio Related Terms


Orgenesis Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Orgenesis's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orgenesis Cyclically Adjusted PB Ratio Chart

Orgenesis Annual Data
Trend Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.16 2.94 1.67 0.39 0.00

Orgenesis Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.63 0.46 0.34 0.00

STU:45O0 vs ENDV, GBLX, OMGAQ: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Orgenesis's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orgenesis Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Orgenesis's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Orgenesis's Cyclically Adjusted PB Ratio falls into.


STU:45O0
12GF Score
Orgenesis Inc STU:45O0
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orgenesis Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Orgenesis's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2024 is calculated as:

For example, Orgenesis's adjusted Book Value per Share data for the three months ended in Dec. 2024 was:

Adj_Book=Book Value per Share/CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=-6.926/315.6050*315.6050
=-6.926

Current CPI (Dec. 2024) = 315.6050.

Orgenesis Quarterly Data

Book Value per Share CPI Adj_Book
201502 -6.850 234.722 -9.210
201505 -9.695 237.805 -12.867
201508 -11.510 238.316 -15.243
201511 -12.908 237.336 -17.165
201602 16.608 237.111 22.106
201605 14.871 240.229 19.537
201608 13.327 240.849 17.464
201611 12.182 241.353 15.930
201702 5.521 243.603 7.153
201705 9.030 244.733 11.645
201708 9.695 245.519 12.463
201711 12.191 246.669 15.598
201802 15.362 248.991 19.472
201805 16.412 251.588 20.588
201808 18.836 252.146 23.577
201811 16.688 252.038 20.897
201903 11.412 254.202 14.169
201906 8.847 256.143 10.901
201909 5.888 256.759 7.237
201912 3.054 256.974 3.751
202003 44.123 258.115 53.951
202006 35.469 257.797 43.423
202009 33.306 260.280 40.386
202012 17.845 260.474 21.622
202103 18.771 264.877 22.366
202106 17.372 271.696 20.180
202109 14.934 274.310 17.182
202112 14.029 278.802 15.881
202203 12.695 287.504 13.936
202206 12.102 296.311 12.890
202209 11.943 296.808 12.699
202212 10.183 296.797 10.828
202303 9.275 301.836 9.698
202306 7.770 305.109 8.037
202309 3.812 307.789 3.909
202312 -6.035 306.746 -6.209
202403 -7.426 312.332 -7.504
202406 -3.068 314.175 -3.082
202409 -4.513 315.301 -4.517
202412 -6.926 315.605 -6.926

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Orgenesis Business Description

Address 20271 Goldenrod Lane, Germantown, MD, USA, 20876
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Octomera and Therapies. The company's therapies pipeline includes Immuno-Oncology, Viral Diseases, Metabolic & Autoimmune Diseases, Vascular & Musculoskeletal Diseases, and Kidney Disease.
12GF Score

Get the complete analysis for STU:45O0

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.40
Price